id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-290127-51ljxy72	Al-Kassmy, Jawad	Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?	2020-08-07		.txt	text/plain	7368	369	46	While the S protein is by far the most studied region for vaccine designs, in silico analyses of potential immunogenic epitopes in the SARS-CoV-2 have suggested several domains within the N, M, and E protein as well as the non-structural proteins primarily focusing on T cell responses [21] [22] [23] [24] [25] . Looking at SARS, several vaccines using different viral vectors or DNA were able to induce high levels of neutralizing antibodies using the full-length S protein, which, in some models, provided protection against challenge [36] [37] [38] [39] [40] . When comparing different vaccine platforms, one study looked at the inactivated vaccines and adenovirus vectors expressing the S protein, or the N protein of SARS reported increased protection when utilizing the whole inactivated virus. A Phase I/II, randomized, placebo-controlled, observer-blind, dose-finding trial in the United States (NCT04368728/NCT04380701) is evaluating the safety, tolerability, immunogenicity, and efficacy of four SARS-CoV-2 RNA vaccine candidates (BNT162a1, BNT162b1, BNT162b2, and BNT162c2) in healthy adults between 18 and 85 years old.	./cache/cord-290127-51ljxy72.txt	./txt/cord-290127-51ljxy72.txt